Combined pergolide-associated valvular heart disease (PAVHD) and Achilles tendon contractures


  • William D. Freeman
  • Peter T. Dorsher
  • Robert E. Safford
  • Jay Van Gerpen
  • William D. Edwards


A Letter to Editor


Download data is not yet available.


Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol. 2007;6(9):826-9.

Hu MT, Bland J, Clough C, Ellis CM, Chaudhuri KR. Limb contractures in levodopa-responsive parkinsonism: a clinical and investigational study of seven new cases. J Neurol. 1999;246(8):671-6.

Charcot JM. Lectures on the diseases of the nervous system (paralysis agitans), lecture V. London: New Sydenham Society; 1877. p. 140-7.

Hofmann C, Penner U, Dorow R, Pertz HH, Jähnichen S, Horowski R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in

cardiac valvular fibrosis. Clin Neuropharmacol. 2006;29(2):80-6.

Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39-46.

Fukae J, Tanaka S, Hattori N. Retroperitoneal fibrosis secondary to pergolide therapy. Intern Med. 2010;49(15):1687.




How to Cite

Freeman, W. D., Dorsher, P. T., Safford, R. E., Van Gerpen, J., & Edwards, W. D. (2012). Combined pergolide-associated valvular heart disease (PAVHD) and Achilles tendon contractures. Acta Medica Academica, 41(2), 228–230. Retrieved from



Letter to Editor